L-DOPA (L-3,4-dihydroxyphenylalanine) remains the most effective drug for the treatment of Parkinson's disease. However, chronic use causes dyskinesia, a complex motor phenomenon that consists of ...

Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...

Valentino Stella served as a consultant in developing Vyalev, which is delivered subcutaneously to Parkinson’s patients through a wearable pump that’s smaller, more comfortable and effective at ...

NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...

Previous studies in a rat model of Parkinson disease (PD) have shown that dyskinesia induced by L-DOPA—a treatment-limiting adverse effect of long-term administration—is caused by the release ...

The use of this drug is limited by the development of psychiatric ... More information: Carina Plewnia et al, Rewarding properties of L-Dopa in experimental parkinsonism are mediated by sensitized ...

The odds ratio for exposure to L-dopa in the IPD patients with PN was 12.4 (95% confidence interval, 1.4–109.1). There were no differences between the groups in the use of other PD drugs ...

Symptomatic drug therapy should be initiated when parkinsonian symptoms become bothersome to the patient. L-dopa remains the most powerful antiparkinsonian agent, but a minority of treated ...